Table 1 Characteristics of patients who received posaconazole oral suspension
Characteristic | PAP (n = 93) | SAP (n = 30) | P value |
|---|---|---|---|
Previous IFD | |||
Proven | 5 (16.7) | ||
Probable | 13 (10.6) | ||
Possible | 12 (9.8) | ||
Age at transplantation (y) | 0.821 | ||
Median (range) | 38 (14–72) | 40 (18–68) | 0.258 |
Gender, no. (%) | 0.975 | ||
Male | 53 (57.0) | 17 (56.7) | |
Female | 40 (43.0) | 13 (43.3) | |
Underlying disease, no. (%) | 0.067 | ||
AML | 30 (32.3) | 11 (36.7) | |
ALL | 21 (22.6) | 12 (40.0) | |
Othera | 42 (45.2) | 7 (23.3) | |
Complication, no. (%) | 0.518 | ||
Diabetes | 11 (11.8) | 2 (6.7) | |
No diabetes | 82 (88.2) | 28 (93.3) | |
Stage of underlying disease, no. (%) | 1.0 | ||
CR | 78 (83.9) | 25 (83.3) | |
Non-CR | 15 (16.1) | 5 (16.7) | |
Transplant type, no. (%) | 10 (33.3) | 20 (66.7) | 0.655 |
MSD | 27 (29.0) | 10 (33.3) | |
HID | 66 (71.0) | 20 (66.7) | |
Conditioning regimen, no. (%) | 1.0 | ||
Myeloablative | 81 (87.1) | 26 (86.7) | |
Reduced intensity | 12 (12.9) | 4 (13.3) | |
GVHD prophylaxis, no. (%) | 0.394 | ||
ATG-based | 75 (80.6) | 22 (73.3) | |
Non-ATG based | 18 (19.4) | 8 (26.7) | |
Acute GVHD | 0.624 | ||
Grades 0–II | 78 (83.9) | 24 (80) | |
Grades III–IV | 15 (16.1) | 6 (20) | |
Chronic GVHD | 0.388 | ||
No/limited | 67 (72) | 24 (80) | |
Extensive | 26 (28) | 6 (20) | |
Reduced intensity | 12 (12.9) | 4 (13.3) | |
GVHD prophylaxis, no. (%) | 0.394 | ||
ATG-based | 75 (80.6) | 22 (73.3) | |
Non-ATG based | 18 (19.4) | 8 (26.7) | |
Acute GVHD | 0.624 | ||
Grades 0–II | 78 (83.9) | 24 (80) | |
Grades III–IV | 15 (16.1) | 6 (20) | |
Chronic GVHD | 0.388 | ||
No/limited | 67 (72) | 24 (80) | |
Extensive | 26 (28) | 6 (20) | |
Reduced intensity | 12 (12.9) | 4 (13.3) | |
GVHD prophylaxis, no. (%) | 0.394 | ||
ATG-based | 75 (80.6) | 22 (73.3) | |
Non-ATG based | 18 (19.4) | 8 (26.7) | |
Acute GVHD | 0.624 | ||
Grades 0–II | 78 (83.9) | 24 (80) | |
Grades III–IV | 15 (16.1) | 6 (20) | |
Chronic GVHD | 0.388 | ||
No/limited | 67 (72) | 24 (80) | |
Extensive | 26 (28) | 6 (20) |